Announcements Trials
Browse Landscape

Phase

Phase 1/2 2Phase 2 1

Status

Recruiting 3Withdrawn 2Unknown 2Not yet recruiting 2Completed 2Active not recruiting 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Sarcoma 1Gynecologic 1

Conditions

Sarcoma, Ewing 1Endometrial Neoplasms 1

Interventions

Cyclophosphamide 28pembrolizumab 22Bevacizumab 18Fluorouracil 17Cisplatin 17Nivolumab 16Capecitabine 16Leucovorin 15Dexamethasone 14Carboplatin 13avelumab 12Oxaliplatin 12Radiosurgery 11Gemcitabine 11Rituximab 10Radiotherapy 10Lenalidomide 10ALT-803 10venetoclax 9fludarabine 9Taxes 9Omacor 9Azacitidine 9130-nm albumin-bound paclitaxel 9Paclitaxel 8Docetaxel 8Bortezomib 8fludarabine phosphate 7Melphalan 7Irinotecan 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1/2 × Withdrawn × PM 01183 × Clear all
NCT06385548 2025-04-01

LiDer

Vall d'Hebron Institute of Oncology

Phase 1/2 Withdrawn
Gynecologic

Endometrial Neoplasms

NCT05042934 2022-02-10

Lurbinectedin With or Without Irinotecan in Treating Patients With Relapsed or High Risk Metastatic Ewing Sarcoma

M.D. Anderson Cancer Center

Phase 1/2 Withdrawn
Sarcoma

Sarcoma, Ewing

Data powered by HemOnc (CC BY 4.0) Colophon âš¡